Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Molecular Cancer|May 28, 2023
IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expressionSven Hagemann, Danny Misiak, Jessica L Bell, et al.
Nucleic Acids Research|August 8, 2020
The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancerSimon Müller, Nadine Bley, Bianca Busch, et al.
Oncoimmunology|March 24, 2026
Sex determines the natural killer cell-mediated immunity against pancreatic cancerElise Arlt, Nadine Bley, Alexander Rausch, et al.
Cancer Cell|December 3, 2016
UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and MetastasisLaurence Wurth, Panagiotis Papasaikas, David Olmeda, et al.
Nucleic Acids Research|July 18, 2022
Melanoma RBPome identification reveals PDIA6 as an unconventional RNA-binding protein involved in metastasisNeus Mestre-Farràs, Santiago Guerrero, Nadine Bley, et al.
NAR Cancer|July 28, 2021
Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in miceSimon Müller, Alice Wedler, Janina Breuer, et al.
Hepatology (Baltimore, Md.)|January 8, 2014
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinomaTony Gutschner, Monika Hämmerle, Nikolaos Pazaitis, et al.
RNA Biology|September 3, 2020
IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancerNadine Bley, Annekatrin Schott, Simon Müller, et al.
Cancer Research|March 8, 2022
Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic LeukemiaTill Braun, Johanna Stachelscheid, Nadine Bley, et al.
Nature Communications|May 18, 2022
HDLBP binds ER-targeted mRNAs by multivalent interactions to promote protein synthesis of transmembrane and secreted proteinsUlrike Zinnall, Miha Milek, Igor Minia, et al.
Pageof 3